<p>隨着全球市場經歷主要指數創下新高和經濟指標波動的混合狀態，投資者密切關注小型股的表現，例如在羅素 2000 指數中的股票，這些股票在更廣泛的市場波動中顯示出積極的走勢。在這個動態環境中，識別未被發現的潛力股——那些由於堅實的基本面和戰略定位而具有增長潛力的股票——可以有效增強投資組合的韌性和多樣性。</p>
<h3>全球十大未被發現的基本面強勁的潛力股</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brillian Network \u0026 Automation Integrated System</td>
<td>NA</td>
<td>22.16%</td>
<td>22.91%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ManpowerGroup Greater China</td>
<td>NA</td>
<td>15.01%</td>
<td>0.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>14.55%</td>
<td>29.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema Chemicals International</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Fengyinhe Holdings</td>
<td>0.60%</td>
<td>39.37%</td>
<td>65.41%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>National Corporation for Tourism and Hotels</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Saudi Chemical Holding</td>
<td>79.49%</td>
<td>16.57%</td>
<td>44.01%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球未被發現的基本面強勁的潛力股篩選器中的 3163 只股票的完整列表。</p>
<p>讓我們探索篩選結果中的幾個突出選項。</p>
<h2>東北製藥集團 (SZSE:000597)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 東北製藥集團有限公司在中國從事化學制藥製劑、製藥業務、製藥工程和生物醫學領域的運營，市值為 86.6 億人民幣。</p>
<p><strong>運營：</strong> 東北製藥集團主要通過其化學制藥製劑和製藥業務部門產生收入。該公司的淨利潤率經歷了波動，反映出運營效率和成本管理的變化。</p>
<p>東北製藥集團在過去一年中顯示出良好的增長跡象，盈利增長率為 12.3%，超過行業平均水平的-2.5%。公司的負債權益比在五年內顯著降低，從 94% 降至 37.5%，表明財務狀況更強。其市盈率為 23.2 倍，低於中國市場平均水平的 41.8 倍，暗示其相對於同行可能被低估。儘管 2025 年第一季度淨收入從去年的 5800 萬人民幣降至 3600 萬人民幣，但它仍然產生正的自由現金流，並保持高質量的盈利。</p>
<ul>
<li>點擊探索我們在東北製藥集團健康報告中的詳細發現。</li>
<li>瞭解東北製藥集團的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/256e9d33-79b2-46c8-b8c0-059939fce028/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/256e9d33-79b2-46c8-b8c0-059939fce028/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:000597 截至 2025 年 7 月的盈利和收入增長</p>
<h2>築博設計 (SZSE:300564)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 築博設計有限公司在中國提供建築設計和諮詢服務，市值為 33.7 億人民幣。</p>
<p><strong>運營：</strong> 該公司主要通過建築設計和諮詢服務產生收入，市值為 33.7 億人民幣，專注於提供專業設計解決方案。</p>
<p>築博設計作為專業服務行業中的小型參與者，展現出引人注目的財務動態。去年盈利增長 28%，超過行業平均水平的-0.5%，儘管五年內年均下降 19.8%。該公司保持無債務狀態，減輕了對利息支付的擔憂，使其能夠專注於運營增長。最近報告的第一季度銷售額為 5794 萬人民幣，淨虧損從去年的 5350 萬人民幣減少至 2768 萬人民幣，表明在股價波動和一次性收益 5870 萬人民幣影響近期業績的情況下，運營有所改善。</p>
<ul>
<li>點擊這裏發現築博設計的細微差別，查看我們的詳細分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取對築博設計過去表現的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ebf3a1e9-89b4-4359-9481-7b2346cb4bf4/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ebf3a1e9-89b4-4359-9481-7b2346cb4bf4/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300564 截至 2025 年 7 月的盈利和收入增長</p>
<h2>山東大學電力技術 (SZSE:301609)</h2>
<p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 山東大學電力技術有限公司從事電力技術解決方案的開發和提供，市值為 23.9 億人民幣。</p>
<p><strong>運營：</strong> 山東大學電力技術主要通過其電力技術解決方案產生收入。該公司的市值為 23.9 億人民幣，表明其在行業中的規模。</p>
<p>山東大學電力技術作為電氣行業中的靈活參與者，在過去一年中展現出 19.4% 的顯著盈利增長，超過行業平均水平的-1.2%。該公司無債務交易，且交易價格低於其估計的公允價值 21.1%，表明市場可能低估。最近完成了一筆價值 5.37 億人民幣的首次公開募股，股票定價為 14.66 人民幣，儘管其流動性較低且缺乏近期財務數據更新，但似乎有進一步擴展的潛力。該公司報告了高質量的盈利，在當前挑戰中呈現出引人注目的機會。</p>
<ul>
<li>通過我們的綜合健康報告，深入瞭解山東大學電力技術的複雜性。</li>
<li>通過查看我們的歷史業績報告，獲取山東大學電力技術的歷史表現洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f87b60c-2f2a-4e58-aece-5e623eddf3dc/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f87b60c-2f2a-4e58-aece-5e623eddf3dc/chart/debt-equity-history-analysis"/></p>
<p>SZSE:301609 截至 2025 年 7 月的債務與股本比率</p>
<h2>讓它發生</h2>
<ul>
<li>點擊這裏，仔細查看我們全球未被發現的強基本面公司名單，共 3163 家公司。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受覆蓋每個大洲的基本市場情報的免費訪問。</li>
</ul>
<h2>尋找替代機會？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

築博設計

<p>隨着全球市場波動，投資者正關注像羅素 2000 指數中的小型股。識別具有強大基本面的未被發現的潛力股可以增強投資組合的韌性。值得注意的公司包括東北製藥集團、築博設計和山東大學電力科技，這些公司都顯示出良好的盈利增長和潛在的低估。這些公司在各自的行業中位置良好，使其成為在市場波動中尋求增長機會的投資者的吸引選項</p>

<p>As global markets experience a mix of record highs in major indices and fluctuating economic indicators, investors are keenly observing the performance of small-cap stocks like those in the Russell 2000, which have shown positive movement amidst broader market volatility. In this dynamic environment, identifying undiscovered gems—stocks that offer potential for growth due to solid fundamentals and strategic positioning—can be an effective way to enhance your portfolio's resilience and diversity.</p>
<div class="lb-trans"><p>隨着全球市場經歷主要指數創下新高和經濟指標波動的混合狀態，投資者密切關注小型股的表現，例如在羅素 2000 指數中的股票，這些股票在更廣泛的市場波動中顯示出積極的走勢。在這個動態環境中，識別未被發現的潛力股——那些由於堅實的基本面和戰略定位而具有增長潛力的股票——可以有效增強投資組合的韌性和多樣性。</p>
</div><h3>Top 10 Undiscovered Gems With Strong Fundamentals Globally</h3>
<div class="lb-trans"><h3>全球十大未被發現的基本面強勁的潛力股</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Debt To Equity</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Health Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brillian Network &amp; Automation Integrated System</td>
<td>NA</td>
<td>22.16%</td>
<td>22.91%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ManpowerGroup Greater China</td>
<td>NA</td>
<td>15.01%</td>
<td>0.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>14.55%</td>
<td>29.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema Chemicals International</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Fengyinhe Holdings</td>
<td>0.60%</td>
<td>39.37%</td>
<td>65.41%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>National Corporation for Tourism and Hotels</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Saudi Chemical Holding</td>
<td>79.49%</td>
<td>16.57%</td>
<td>44.01%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>負債權益比</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>健康評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brillian Network \u0026 Automation Integrated System</td>
<td>NA</td>
<td>22.16%</td>
<td>22.91%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Saha-Union</td>
<td>0.84%</td>
<td>0.90%</td>
<td>15.45%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>ManpowerGroup Greater China</td>
<td>NA</td>
<td>15.01%</td>
<td>0.09%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>National General Insurance (P.J.S.C.)</td>
<td>NA</td>
<td>14.55%</td>
<td>29.05%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>TSTE</td>
<td>36.22%</td>
<td>3.96%</td>
<td>-8.49%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Practic</td>
<td>5.21%</td>
<td>4.49%</td>
<td>7.23%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Mechema Chemicals International</td>
<td>55.74%</td>
<td>-4.23%</td>
<td>-5.72%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Fengyinhe Holdings</td>
<td>0.60%</td>
<td>39.37%</td>
<td>65.41%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>National Corporation for Tourism and Hotels</td>
<td>19.25%</td>
<td>0.67%</td>
<td>4.89%</td>
<td>★★★★☆☆</td>
</tr>
<tr>
<td>Saudi Chemical Holding</td>
<td>79.49%</td>
<td>16.57%</td>
<td>44.01%</td>
<td>★★★★☆☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3163 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球未被發現的基本面強勁的潛力股篩選器中的 3163 只股票的完整列表。</p>
</div><p>Let's explore several standout options from the results in the screener.</p>
<div class="lb-trans"><p>讓我們探索篩選結果中的幾個突出選項。</p>
</div><h2>Northeast Pharmaceutical Group (SZSE:000597)</h2>
<div class="lb-trans"><h2>東北製藥集團 (SZSE:000597)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Northeast Pharmaceutical Group Co., Ltd. operates in the fields of chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, and biomedicine in China with a market cap of CN¥8.66 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 東北製藥集團有限公司在中國從事化學制藥製劑、製藥業務、製藥工程和生物醫學領域的運營，市值為 86.6 億人民幣。</p>
</div><p><strong>Operations:</strong> Northeast Pharmaceutical Group generates revenue primarily from its chemical pharmaceuticals preparations and pharmaceutical business segments. The company has observed fluctuations in its net profit margin, reflecting changes in operational efficiency and cost management.</p>
<div class="lb-trans"><p><strong>運營：</strong> 東北製藥集團主要通過其化學制藥製劑和製藥業務部門產生收入。該公司的淨利潤率經歷了波動，反映出運營效率和成本管理的變化。</p>
</div><p>Northeast Pharmaceutical Group is showing promising signs with its earnings growth of 12.3% over the past year, outpacing the industry average of -2.5%. The company's debt to equity ratio has impressively reduced from 94% to 37.5% in five years, indicating a stronger financial position. Its price-to-earnings ratio stands at 23.2x, which is below the CN market average of 41.8x, suggesting it could be undervalued relative to peers. Despite a drop in net income for Q1 2025 to CNY 36 million from CNY 58 million last year, it continues to generate positive free cash flow and maintain high-quality earnings.</p>
<div class="lb-trans"><p>東北製藥集團在過去一年中顯示出良好的增長跡象，盈利增長率為 12.3%，超過行業平均水平的-2.5%。公司的負債權益比在五年內顯著降低，從 94% 降至 37.5%，表明財務狀況更強。其市盈率為 23.2 倍，低於中國市場平均水平的 41.8 倍，暗示其相對於同行可能被低估。儘管 2025 年第一季度淨收入從去年的 5800 萬人民幣降至 3600 萬人民幣，但它仍然產生正的自由現金流，並保持高質量的盈利。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Northeast Pharmaceutical Group's health report.</li>
<li>Learn about Northeast Pharmaceutical Group's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在東北製藥集團健康報告中的詳細發現。</li>
<li>瞭解東北製藥集團的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/256e9d33-79b2-46c8-b8c0-059939fce028/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/256e9d33-79b2-46c8-b8c0-059939fce028/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:000597 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:000597 截至 2025 年 7 月的盈利和收入增長</p>
</div><h2>Zhubo Design (SZSE:300564)</h2>
<div class="lb-trans"><h2>築博設計 (SZSE:300564)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhubo Design Co., Ltd provides architectural design and consulting services in China, with a market cap of CN¥3.37 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 築博設計有限公司在中國提供建築設計和諮詢服務，市值為 33.7 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from architectural design and consulting services in China. With a market cap of CN¥3.37 billion, it focuses on providing specialized design solutions.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過建築設計和諮詢服務產生收入，市值為 33.7 億人民幣，專注於提供專業設計解決方案。</p>
</div><p>Zhubo Design, a smaller player in the professional services sector, has shown intriguing financial dynamics. Earnings surged 28% last year, outpacing the industry average of -0.5%, despite a 19.8% annual decrease over five years. The company remains debt-free, alleviating concerns about interest payments and allowing focus on operational growth. Recently reported sales for Q1 were CN¥57.94 million, with a net loss reduced to CN¥27.68 million from CN¥53.5 million the previous year, indicating some operational improvement amidst volatility in share price and one-off gains of CN¥58.7 million affecting recent results.</p>
<div class="lb-trans"><p>築博設計作為專業服務行業中的小型參與者，展現出引人注目的財務動態。去年盈利增長 28%，超過行業平均水平的-0.5%，儘管五年內年均下降 19.8%。該公司保持無債務狀態，減輕了對利息支付的擔憂，使其能夠專注於運營增長。最近報告的第一季度銷售額為 5794 萬人民幣，淨虧損從去年的 5350 萬人民幣減少至 2768 萬人民幣，表明在股價波動和一次性收益 5870 萬人民幣影響近期業績的情況下，運營有所改善。</p>
</div><ul>
<li>Click here to discover the nuances of Zhubo Design with our detailed analytical health report.</li>
<li>Review our historical performance report to gain insights into Zhubo Design's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現築博設計的細微差別，查看我們的詳細分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取對築博設計過去表現的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ebf3a1e9-89b4-4359-9481-7b2346cb4bf4/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ebf3a1e9-89b4-4359-9481-7b2346cb4bf4/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300564 Earnings and Revenue Growth as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:300564 截至 2025 年 7 月的盈利和收入增長</p>
</div><h2>Shandong University Electric Power Technology (SZSE:301609)</h2>
<div class="lb-trans"><h2>山東大學電力技術 (SZSE:301609)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 價值評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Shandong University Electric Power Technology Co., Ltd. is engaged in the development and provision of electric power technology solutions, with a market cap of CN¥2.39 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山東大學電力技術有限公司從事電力技術解決方案的開發和提供，市值為 23.9 億人民幣。</p>
</div><p><strong>Operations:</strong> Shandong University Electric Power Technology generates revenue primarily through its electric power technology solutions. The company has a market capitalization of CN¥2.39 billion, indicating its scale within the industry.</p>
<div class="lb-trans"><p><strong>運營：</strong> 山東大學電力技術主要通過其電力技術解決方案產生收入。該公司的市值為 23.9 億人民幣，表明其在行業中的規模。</p>
</div><p>Shandong University Electric Power Technology, a nimble player in the electrical industry, has demonstrated impressive earnings growth of 19.4% over the past year, outpacing the industry average of -1.2%. This company stands debt-free and trades at 21.1% below its estimated fair value, indicating potential undervaluation in the market. Recently completing an IPO worth CNY 537 million with shares priced at CNY 14.66 each, it seems poised for further expansion despite its highly illiquid shares and lack of recent financial data updates. With high-quality earnings reported, this firm presents an intriguing opportunity amidst its current challenges.</p>
<div class="lb-trans"><p>山東大學電力技術作為電氣行業中的靈活參與者，在過去一年中展現出 19.4% 的顯著盈利增長，超過行業平均水平的-1.2%。該公司無債務交易，且交易價格低於其估計的公允價值 21.1%，表明市場可能低估。最近完成了一筆價值 5.37 億人民幣的首次公開募股，股票定價為 14.66 人民幣，儘管其流動性較低且缺乏近期財務數據更新，但似乎有進一步擴展的潛力。該公司報告了高質量的盈利，在當前挑戰中呈現出引人注目的機會。</p>
</div><ul>
<li>Navigate through the intricacies of Shandong University Electric Power Technology with our comprehensive health report here.</li>
<li>Gain insights into Shandong University Electric Power Technology's historical performance by reviewing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合健康報告，深入瞭解山東大學電力技術的複雜性。</li>
<li>通過查看我們的歷史業績報告，獲取山東大學電力技術的歷史表現洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6f87b60c-2f2a-4e58-aece-5e623eddf3dc/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6f87b60c-2f2a-4e58-aece-5e623eddf3dc/chart/debt-equity-history-analysis"/></p>
<p>SZSE:301609 Debt to Equity as at Jul 2025</p>
<div class="lb-trans"><p>SZSE:301609 截至 2025 年 7 月的債務與股本比率</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Take a closer look at our Global Undiscovered Gems With Strong Fundamentals list of 3163 companies by clicking here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏，仔細查看我們全球未被發現的強基本面公司名單，共 3163 家公司。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時瞭解您股票的任何重要更新。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受覆蓋每個大洲的基本市場情報的免費訪問。</li>
</ul>
</div><h2>Looking For Alternative Opportunities?</h2>
<div class="lb-trans"><h2>尋找替代機會？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

全球市場中有 3 個未被發現的寶石可以提升您的投資組合